These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 11247905)

  • 1. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.
    Nugent SG; Kumar D; Rampton DS; Evans DF
    Gut; 2001 Apr; 48(4):571-7. PubMed ID: 11247905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanded table: Some drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2023 Jul; 65(1680):e115-e119. PubMed ID: 37418332
    [No Abstract]   [Full Text] [Related]  

  • 3. Drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2023 Jul; 65(1680):105-112. PubMed ID: 37418329
    [No Abstract]   [Full Text] [Related]  

  • 4. Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?
    van Bodegraven AA; Mulder CJ
    World J Gastroenterol; 2006 Oct; 12(38):6115-23. PubMed ID: 17036381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panuveitis in a patient with active Crohn's disease.
    Senthamizh T; Senthamizhselvan K; Sahoo NK; Kaliaperumal S
    BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33541992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory bowel disease: perioperative pharmacological considerations.
    Kumar A; Auron M; Aneja A; Mohr F; Jain A; Shen B
    Mayo Clin Proc; 2011 Aug; 86(8):748-57. PubMed ID: 21803957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota-driven drug metabolism in inflammatory bowel disease.
    Crouwel F; Buiter HJC; de Boer NK
    J Crohns Colitis; 2020 Jul; 15(2):307-15. PubMed ID: 32652007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal pH profiles in patients with inflammatory bowel disease.
    Press AG; Hauptmann IA; Hauptmann L; Fuchs B; Fuchs M; Ewe K; Ramadori G
    Aliment Pharmacol Ther; 1998 Jul; 12(7):673-8. PubMed ID: 9701532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very low intraluminal colonic pH in patients with active ulcerative colitis.
    Fallingborg J; Christensen LA; Jacobsen BA; Rasmussen SN
    Dig Dis Sci; 1993 Nov; 38(11):1989-93. PubMed ID: 8223071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels.
    Abinusawa A; Tenjarla S
    Adv Ther; 2015 May; 32(5):477-84. PubMed ID: 25951927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn's disease.
    Sasaki Y; Hada R; Nakajima H; Fukuda S; Munakata A
    Am J Gastroenterol; 1997 Jan; 92(1):114-8. PubMed ID: 8995949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymeric chloroquine as an inhibitor of cancer cell migration and experimental lung metastasis.
    Yu F; Li J; Xie Y; Sleightholm RL; Oupický D
    J Control Release; 2016 Dec; 244(Pt B):347-356. PubMed ID: 27473763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of chloroquine in a murine model of inflammatory bowel disease.
    Nagar J; Ranade S; Kamath V; Singh S; Karunanithi P; Subramani S; Venkatesh K; Srivastava R; Dudhgaonkar S; Vikramadithyan RK
    Int Immunopharmacol; 2014 Aug; 21(2):328-35. PubMed ID: 24859061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: the limitations of corticosteroid therapy in Crohn's disease.
    Rutgeerts PJ
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1515-25. PubMed ID: 11563990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue.
    Hua S; Marks E; Schneider JJ; Keely S
    Nanomedicine; 2015 Jul; 11(5):1117-32. PubMed ID: 25784453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis.
    Varshosaz J; Emami J; Tavakoli N; Fassihi A; Minaiyan M; Ahmadi F; Dorkoosh F
    Int J Pharm; 2009 Jan; 365(1-2):69-76. PubMed ID: 18804521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxychloroquine retinopathy: an emerging problem.
    Latasiewicz M; Gourier H; Yusuf IH; Luqmani R; Sharma SM; Downes SM
    Eye (Lond); 2017 Jun; 31(6):972-976. PubMed ID: 28186509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory activity of chloroquine and amodiaquine through p21-mediated suppression of T cell proliferation and Th1 cell differentiation.
    Oh S; Shin JH; Jang EJ; Won HY; Kim HK; Jeong MG; Kim KS; Hwang ES
    Biochem Biophys Res Commun; 2016 May; 474(2):345-350. PubMed ID: 27109480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease.
    Malayandi R; Kondamudi PK; Ruby PK; Aggarwal D
    Drug Deliv Transl Res; 2014 Apr; 4(2):187-202. PubMed ID: 25786732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.